Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 March 2014

  • Email
  • Help

News

07/03/2014

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 March 2014

The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) gave recommendations on three safety referrals at its March 2014 meeting.

PRAC recommends restricting use of domperidone

The PRAC has concluded an in-depth review of domperidone-containing medicines, carried out over concerns about the medicines' effects on the heart. The Committee has recommended changes to their use throughout the European Union (EU), including using these medicines only to relieve symptoms of nausea and vomiting, restricting the dose and adjusting doses carefully by weight where it is licensed in children.

More information on this topic is available in the table below.

Following re-examination, PRAC recommends diacerein remain available with restrictions

The PRAC has also recommended that diacerein-containing medicines remain available but with restrictions to manage the risks of severe diarrhoea and effects on the liver. These recommendations are the outcome of a re-examination of the PRAC’s November 2013 opinion to suspend marketing authorisations for diacerein.

More information on this topic is available in the table below.

PRAC recommends updates to the product information of zolpidem

The PRAC has recommended changes to the product information of zolpidem-containing medicines. These changes are aimed at further minimising the known risks of next-morning impaired driving ability and mental alertness (including somnambulism) with these medicines.

More information on this topic is available in the table below.

Agenda

 
Agenda - PRAC draft agenda of meeting 3-6 March 2014

 

Recommendations by PRAC

Diacerein

Article-31 referral: Diacerein-containing medicines for oral administration

 

Summary of PRAC recommendation

 

Domperidone

Article-31 referral: Domperidone-containing medicinal products

 

Summary of PRAC recommendation

 

Zolpidem

Article-31 referral: Zolpidem-containing medicinal products

 

Summary of PRAC recommendation

How useful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings

Related information

Contact point:

Monika Benstetter
Tel. +44 (0)20 7418 8427
E-mail: press@ema.europa.eu